fenebrutinib   Click here for help

GtoPdb Ligand ID: 9299

Synonyms: Example 130 [US20140194408] | GDC-0853 | GDC0853 | RG-7845 | RG7845
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Fenebrutinib (RG7845, GDC-0853) is a reversible Bruton's tyrosine kinase (BTK) inhibitor, under investigation for therapeutic potential in difficult-to-treat autoimmune diseases, including multiple sclerosis [7]. The compound is claimed in patent WO2013067274 [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 120.99
Molecular weight 664.35
XLogP 5.44
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES OCc1c(ccnc1N1CCn2c(C1=O)cc1c2CC(C1)(C)C)c1cc(Nc2ccc(cn2)N2CCN(CC2C)C2COC2)c(=O)n(c1)C
Isomeric SMILES OCc1c(ccnc1N1CCn2c(C1=O)cc1c2CC(C1)(C)C)c1cc(Nc2ccc(cn2)N2CCN(C[C@@H]2C)C2COC2)c(=O)n(c1)C
InChI InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1
No information available.
Summary of Clinical Use Click here for help
GDC-0853 was reported to be well tolerated with no dose-limiting adverse events in phase 1 studies in healthy volunteers [3]. It was advanced to clinical evaluations is patients with B-cell malignancies, and to determine efficacy against difficult-to-treat autoimmune or inflammatory conditions. GDC-0853 has demonstrated efficacy to reduce brain lesions in multiple sclerosis in phase 2 clinical study (NCT05119569) [5] (unpublished findings).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02833350 Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2 Interventional Genentech, Inc.
NCT02908100 A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus Phase 2 Interventional Genentech, Inc. 4
NCT04586023 Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Phase 3 Interventional Hoffmann-La Roche
NCT05119569 A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) Phase 2 Interventional Hoffmann-La Roche